So far, two peptide–radionuclide conjugates, 177Lu-DOTA-TATE and 177Lu-PSMA-617, have been approved for clinical use to treat somatostatin receptors and prostate-specific membrane antigen (PSMA) overexpressing cancers, respectively [22,23]. Here, FOLH1 is linked to cancer.